151. Cerebrospinal fluid HIV-1 viral load during treatment of cryptococcal Meningitis
- Author
-
Weera Mahavanakul, Wirongrong Chierakul, Adul Rajanuwong, Nicholas J. White, Tom Harrison, Annemarie E. Brouwer, Praprit Teparrukkul, and Wasun Chantratita
- Subjects
Colony-forming unit ,Opportunistic infection ,medicine.medical_treatment ,Lymphocyte ,HIV Infections ,Biology ,Meningitis, Cryptococcal ,medicine.disease ,Article ,Infectious Diseases ,Immune system ,Cytokine ,Cerebrospinal fluid ,medicine.anatomical_structure ,Antigen ,Immunology ,medicine ,Cryptococcus neoformans ,HIV-1 ,Humans ,RNA, Viral ,Pharmacology (medical) ,Viral load - Abstract
Human immunodeficiency virus (HIV-1) can be detected in the cerebrospinal fluid (CSF) throughout the course of HIV infection, although at lower concentrations than in blood.1 Opportunistic meningeal infections, such as Cryptococcus neoformans and Mycobacterium tuberculosis can enhance HIV replication in vitro,2-4 and during such infections, HIV-1 viral load (VL) in CSF is found to be raised,5 either as a result of this direct enhancement of replication, and/or increased HIV-1 replication due to a pro-inflammatory immune response and the influx of leucocytes.6 Thus, treatment of the opportunistic infection might lead to a more rapid decline of the HIV-1 VL in the compartment of infection than systemically. To examine the changes in CSF and plasma HIV-1 VL during treatment of cryptococcal meningitis, we measured the levels of HIV-1 RNA in CSF and plasma before and after 2 weeks of treatment of cryptococcal meningitis in 63 Thai patients enrolled in a trial of amphotericin B-based therapy.7 Baseline cryptococcal organism load was determined by quantitative CSF cultures, as were CSF cell count and differential and CSF and plasma cytokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17, G-CSF, GM-CSF, MCP-1, MIP-1β, IFN-γ, and TNF-α)8 to investigate any association of CSF immune parameters with CSF HIV-1 RNA concentrations. CSF was available from 57 patients at baseline and 47 at day 14. Plasma was available from 62 patients at baseline and 49 at day 14. Paired CSF/plasma samples were available of 57 patients at baseline, and 46 at day 14. CSF and plasma samples were centrifuged at 3000 rpm for 10 minutes at 4°C and supernatants were stored at −80°C. The mean time from lumbar puncture to storage at −80°C was less than 3 hours. After collecting all samples, HIV RNA quantification in the cell-free CSF and plasma was performed with the Roche Amplicor Monitor Test (version 1.5, Roche Diagnostic Systems, Hoffman-La Roche, Basel, Switzerland). We compared median log10 HIV-1 RNA concentrations using Wilcoxon matched pairs signed-rank test and the Mann Whitney U test. Correlation between variables was tested using Spearman's rank correlation. Median log10 HIV-1 VL was significantly lower in CSF compared to plasma at baseline and at day 14 (p < 0.001 for both comparisons). There was a significant decrease in HIV-1 VL in both CSF and plasma during the first two weeks of treatment of cryptococcal meningitis (Table). However, the CSF/Plasma HIV-1 VL ratio did not change over time. Baseline CSF HIV-1 VL correlated with CSF lymphocyte count (r=0.5, P=0.0002). At baseline, there was a positive correlation between CSF IL-10 and CSF HIV-1 VL (r=0.6, P
- Published
- 2016